Mirati reports updated Phase II data for sitravatinib, Opdivo combo

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 23 evaluable non-small cell lung cancer (NSCLC) patients who experienced disease progression following prior treatment with a checkpoint inhibitor in a Phase II trial showing that once-daily oral sitravatinib (MGCD516) plus PD-1 inhibitor Opdivo nivolumab led to six partial responses. Additionally, tumor reductions were reported in 19 patients.

The open-label, U.S. trial has enrolled 45 patients. The company plans to report additional data at an oncology conference this year. Mirati previously reported data from 11 evaluable patients in the trial (see BioCentury, Sept. 22, 2017)...